What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?

In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the potential benefits of changing CGRP-targeted trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Waliszewska-Prosół, Marta, Vuralli, Doga, Martelletti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696682/
http://dx.doi.org/10.1186/s10194-023-01698-8
_version_ 1785154618710294528
author Waliszewska-Prosół, Marta
Vuralli, Doga
Martelletti, Paolo
author_facet Waliszewska-Prosół, Marta
Vuralli, Doga
Martelletti, Paolo
author_sort Waliszewska-Prosół, Marta
collection PubMed
description In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the potential benefits of changing CGRP-targeted treatment.
format Online
Article
Text
id pubmed-10696682
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-106966822023-12-06 What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants? Waliszewska-Prosół, Marta Vuralli, Doga Martelletti, Paolo J Headache Pain Editorial In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the potential benefits of changing CGRP-targeted treatment. Springer Milan 2023-12-05 /pmc/articles/PMC10696682/ http://dx.doi.org/10.1186/s10194-023-01698-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Editorial
Waliszewska-Prosół, Marta
Vuralli, Doga
Martelletti, Paolo
What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
title What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
title_full What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
title_fullStr What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
title_full_unstemmed What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
title_short What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
title_sort what to do with non-responders to cgrp(r) monoclonal antibodies: switch to another or move to gepants?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696682/
http://dx.doi.org/10.1186/s10194-023-01698-8
work_keys_str_mv AT waliszewskaprosołmarta whattodowithnonresponderstocgrprmonoclonalantibodiesswitchtoanotherormovetogepants
AT vurallidoga whattodowithnonresponderstocgrprmonoclonalantibodiesswitchtoanotherormovetogepants
AT martellettipaolo whattodowithnonresponderstocgrprmonoclonalantibodiesswitchtoanotherormovetogepants

Ejemplares similares